Quarterly ResultAug 5, 2026, 06:07 AM
Amgen Q2 Revenue $10.05B, Net Income $2.38B, EPS $4.37
AI Summary
Amgen reported strong financial results for the second quarter and first half of 2026. Total revenues for Q2 increased to $10.05 billion, with net income rising to $2.38 billion and diluted EPS reaching $4.37. The company also saw a significant increase in net cash provided by operating activities for the first six months of 2026. Amgen continues to contest substantial IRS tax claims totaling approximately $8.7 billion for prior periods, with a court decision expected in late 2026 or early 2027.
Key Highlights
- Amgen Q2 2026 total revenues rose to $10.05 billion, up from $9.18 billion.
- Q2 2026 net income increased to $2.38 billion, compared to $1.43 billion in Q2 2025.
- Diluted EPS for Q2 2026 was $4.37, up from $2.65 in the prior year period.
- Net cash provided by operating activities for H1 2026 reached $6.19 billion.
- Cash and cash equivalents stood at $13.99 billion as of June 30, 2026.
- Repatha Q2 sales grew to $953 million, up from $696 million in Q2 2025.
- Prolia Q2 sales were $759 million, down from $1.12 billion in Q2 2025.
- Ongoing IRS tax dispute involves potential $8.7 billion in federal tax and penalties.
Price Impact
More from AMGN